doi:10.3945/ajcn.110.003483
Interestingly, His1-Gly2 of exendin-4 exhibited weaker density relative to the rest of the peptide in the cryo-EM map, and this is consistent with the enhanced flexibility observed for this region of the bound peptide in the simulations, likely due to Gly2, as glycine can destabilise -helical conformations
Despite interest in human clinical trials, BPC-157 hasnt yet reached this stage
Patients should not assume that: Every GLP-1 medication has the same cardiovascular outcome evidence Every patient taking a GLP-1 medication is receiving heart-disease treatment Weight loss automatically means all heart risk is resolved Medication can replace blood pressure, cholesterol, or diabetes care Rapid weight loss is always better A lower scale weight is more important than muscle, strength, and labs Side effects should be ignored if weight loss is happening The safest interpretation is more balanced
$130 Billion 1 Projected Market Size of GLP-1 therapies in 2030 10-20% Body Weight Reduction 4 Treatment Breakthrough 42% of U.S
La vitamina B6 contribuye al metabolismo energtico normal, al metabolismo de las protenas, los carbohidratos y los lpidos, y al funcionamiento normal del sistema inmunitario, segn las declaraciones autorizadas por la EFSA (Reglamento (CE) n. 1924/2006)
